Skip to Main Content

TREG

Animal-origin-free proteins for every step of T-Regulatory Cell (TREG) manufacturing.

From leukapheresis to cryopreservation, recombinant albumin, IL-2, transferrin and insulin-transferrin supplements replace serum, bovine albumin and plasma-derived HSA in regulatory T cell manufacturing.

Where InVitria proteins fit in TReg Manufacturing

Regulatory T cells are rare, depend on IL-2 to survive and keep their suppressive identity, and are washed, expanded and frozen in albumin-containing buffers and matrices. Serum, bovine serum albumin, plasma-derived albumin and transferrin, and undefined IL-2 preparations bring run-to-run variability, adventitious-agent risk and animal- or human-derived material into that chain. Defined, animal-origin-free recombinant proteins supply the same functions step by step, from collection to the frozen product.

Where our products fit

The Treg workflow, step by step.

Select any step to see the recommended products grouped by function, and why each one is used.

Starting Material & Cell Source

Procure the patient or donor leukapheresis product as the source of regulatory T cells, and protect the cells during collection and transport with defined, animal-origin-free albumin.

Overview

Starting material and cell source is the first step in regulatory T cell (Treg) therapy. Tregs are a rare CD4+ T cell subset that suppresses immune responses, used to treat autoimmune disease, transplant rejection, and graft-versus-host disease. The starting material is a leukapheresis product from the patient (autologous) or a donor (allogeneic), collected to concentrate mononuclear cells.

Because Tregs are a small fraction of circulating T cells, a large, high-quality apheresis collection matters for recovering enough cells. Handling, time, and temperature between collection and processing affect cell viability and the yield of Tregs available for isolation.

Protecting the cells during this early window supports recovery and a consistent starting point, and a defined, animal-origin-free stabilizing protein avoids introducing serum- or animal-derived material at the start.

Functions

Starting Material Stabilization

Treg therapy starts from a patient or donor leukapheresis product, and Tregs are only a small fraction of the collected cells. Between collection and processing, the cells are exposed to temperature shifts, handling, and surface contact, and viability at this stage affects the yield of Tregs recovered. A stabilizing protein supports cell health through transport and hold, before isolation begins.

Recommendation
Optibumin® 25

Approved excipient 25% recombinant human serum albumin, supplied in bottles and closed-system friendly bags for processing, formulation, cryopreservation, and advanced biomanufacturing.

Commonly replaces
Serum or plasma-derived albumin used to stabilize collected apheresis cells.

Treg Isolation & Enrichment

Enrich regulatory T cells from the apheresis product by CD4 selection and CD25 enrichment, targeting a high-purity CD4+CD25high CD127low population, with animal-origin-free albumin.

Overview

Treg isolation and enrichment recovers the regulatory T cells from the apheresis product. The standard approach is a two-step immunomagnetic selection: depletion of CD8+ and CD19+ cells and selection of CD4+ cells, followed by enrichment of CD25high cells. The target population is CD4+CD25high CD127low FOXP3+.

Purity is critical for Tregs. Contaminating conventional T cells can outgrow Tregs during expansion, so high-purity selection, sometimes by cell sorting, is used. When starting purity is lower, rapamycin is added later in culture to selectively favor Treg outgrowth; rapamycin is not an InVitria product.

A defined, animal-origin-free recombinant albumin protects cells through the selection and washing steps while keeping the process free of serum-derived material.

Functions

Cell Protection & Stabilization

During isolation, cells undergo multi-step magnetic selection or sorting and repeated washing to enrich a high-purity Treg population, which exposes them to selection reagents, centrifugation, and buffer exchange. Albumin supports viability by transporting fatty acids and binding reactive species, buffering cells against handling and oxidative stress as the Treg population is enriched.

Recommendation
Optibumin® 25

Approved excipient 25% recombinant human serum albumin, supplied in bottles and closed-system friendly bags for processing, formulation, cryopreservation, and advanced biomanufacturing.

Commonly replaces
Serum or bovine serum albumin (BSA) in selection and wash buffers.

Cell Activation

Activate Tregs through the T cell receptor and CD28 with anti-CD3/CD28 beads or artificial APCs, with IL-2 and defined albumin supporting the cells from the start.

Overview

Activation delivers the signals Tregs need to enter proliferation. The T cell receptor and CD28 costimulatory signals are provided by anti-CD3/CD28 antibody-coated beads or artificial antigen-presenting cells. These activation reagents are supplied separately and are not InVitria products.
Tregs depend on interleukin-2 (IL-2) more than conventional T cells. They constitutively express the high-affinity IL-2 receptor (CD25) and require IL-2 for survival, proliferation, and maintenance of FOXP3 and suppressive function. IL-2 is added at or shortly after activation and sustained through culture.

A defined, animal-origin-free IL-2 and protein base supports Tregs from activation onward, while keeping the process free of serum- and animal-derived material.

Functions

Cytokine Signaling

Tregs are critically dependent on interleukin-2 (IL-2). Unlike conventional T cells, they produce little IL-2 themselves and rely on an exogenous supply, signaling through their constitutively high-affinity IL-2 receptor (CD25). From activation, IL-2 drives survival and entry into proliferation and sustains FOXP3 expression and suppressive identity. A consistent, defined IL-2 source is central to Treg manufacturing.

Recommendation
OptiLeukin™ 2

Recombinant human interleukin-2 from a non-bacterial expression system for T-cell, Treg, TIL, NK, and γδ T-cell expansion, from research to cGMP manufacturing.

Commonly replaces
Non-recombinant or undefined IL-2 preparations in Treg culture.

Carrier & Protection

Activation moves Tregs from rest into a metabolically active, dividing state, increasing their demand for protein carrier and protection. Albumin binds and transports fatty acids, lipids, and metal ions, contributes antioxidant capacity, and buffers cells against handling stress through activation, supporting viability as the cells respond.

Recommendation
Optibumin® 25

Approved excipient 25% recombinant human serum albumin, supplied in bottles and closed-system friendly bags for processing, formulation, cryopreservation, and advanced biomanufacturing.

Commonly replaces
Serum, human serum albumin (HSA), or bovine serum albumin (BSA) in activation media.

Optional Genetic Modification

Optionally introduce a CAR or T cell receptor to redirect Treg specificity, with defined, animal-origin-free components supporting cells through modification and recovery.

Overview

Genetic modification is an optional step used to redirect Treg specificity. A chimeric antigen receptor (CAR) or a transgenic T cell receptor can be introduced so that Tregs suppress immune responses at a defined target tissue or antigen, rather than acting broadly. Many Treg therapies are polyclonal and skip this step.

The receptor is introduced by viral transduction or by non-viral methods such as mRNA electroporation, performed after activation and before the main expansion so the modified cells expand to dose. The vector and gene-delivery reagents are supplied separately and are not InVitria products.

Gene delivery is a stress on the cells. Maintaining IL-2 signaling and a defined protein base through modification and the recovery that follows supports viability while keeping the process animal-origin-free.

Functions

Transduction Environment Support

Gene transfer, by viral transduction or electroporation, stresses cells and is followed by a recovery window before expansion resumes. Through this window, cells need a defined metabolic base, insulin, transferrin, and selenium, to support recovery and re-entry into proliferation. Maintaining this defined environment supports viability and consistent recovery after modification.

Recommendation
ITSE+A Animal-Free®

Five-component 100x supplement of recombinant insulin, recombinant human transferrin, selenium, ethanolamine, and recombinant human albumin for serum-free cell culture.

Commonly replaces
Serum and undefined supplements in transduction and recovery media.

Cytokine Signaling

Tregs remain IL-2 dependent through genetic modification. Gene transfer and the recovery that follows are demanding, and a sustained IL-2 signal supports survival and re-entry into proliferation while preserving FOXP3 and suppressive identity through the procedure.

Recommendation
OptiLeukin™ 2

Recombinant human interleukin-2 from a non-bacterial expression system for T-cell, Treg, TIL, NK, and γδ T-cell expansion, from research to cGMP manufacturing.

Commonly replaces
Non-recombinant or undefined IL-2 preparations in modified Treg culture.

Treg Expansion

Expand Tregs to clinical numbers with high-dose IL-2 and repeated stimulation, on a defined, animal-origin-free base, while preserving FOXP3 and suppressive function.

Overview

Expansion grows the Tregs to the therapeutic dose. Tregs are expanded for roughly two to five weeks using anti-CD3/CD28 beads or artificial APCs with high-dose IL-2 (commonly 200 to 1000 IU/ml). Rapamycin is often included to suppress outgrowth of contaminating conventional T cells while selectively sparing Tregs; rapamycin is not an InVitria product.

Because Tregs are rare and must stay pure, expansion is demanding: it requires sustained high-dose IL-2, repeated stimulation and feeding, and a defined base of iron, carrier protein, and metabolic components. Some protocols also add TGF-beta to support the Treg phenotype. Outcomes depend on IL-2 supply, culture format, and preserving FOXP3 and suppressive function.

A defined, animal-origin-free expansion strategy supports consistent growth, preserves Treg identity, and reduces the variability that serum and undefined supplements introduce across runs.

Rapamycin is commonly included during expansion to preferentially enrich FOXP3+ regulatory T cells and suppress effector-T-cell outgrowth, alongside high-dose IL-2.

Functions

Cytokine Signaling

Treg expansion depends on sustained high-dose IL-2. Tregs require continuous IL-2 signaling through their high-affinity receptor to proliferate and to preserve FOXP3 and suppressive function, and IL-2 is supplied at high concentration throughout expansion. A consistent, defined IL-2 source is the single most important soluble factor in Treg expansion.

Recommendation
OptiLeukin™ 2

Recombinant human interleukin-2 from a non-bacterial expression system for T-cell, Treg, TIL, NK, and γδ T-cell expansion, from research to cGMP manufacturing.

Commonly replaces
Non-recombinant or undefined IL-2 preparations in Treg expansion.

Iron Transport

Proliferating Tregs require iron for metabolism and DNA synthesis during expansion. In serum-free and defined media, transferrin delivers iron in a controlled, protein-bound form through the transferrin receptor, supporting proliferation while limiting the oxidative stress associated with free iron. Transferrin is a core component of defined T cell media.

Recommendation
Optiferrin®

Recombinant human transferrin, lyophilized, for iron delivery in serum-free and chemically defined media.

Commonly replaces
Serum- or plasma-derived transferrin, and serum as an iron source.

Carrier & Protection

Albumin is the primary protein carrier in defined T cell media. It binds and transports fatty acids, lipids, and metal ions, contributes antioxidant capacity, and buffers cells against the handling and shear of repeated feeding and stimulation through a long expansion. This carrier and protective role supports Treg viability and consistent growth.

Recommendation
Optibumin® 25

Approved excipient 25% recombinant human serum albumin, supplied in bottles and closed-system friendly bags for processing, formulation, cryopreservation, and advanced biomanufacturing.

Commonly replaces
Serum, human serum albumin (HSA), or bovine serum albumin (BSA) in expansion media.

Serum-Free Environment Support

Serum-free expansion depends on a defined metabolic base, insulin for metabolism, transferrin for iron, and selenium for oxidative balance, in place of serum. A blend supplies these in one addition, supporting Treg proliferation while the IL-2 signal and stimulation drive expansion separately.

Recommendation
ITSE+A Animal-Free®

Five-component 100x supplement of recombinant insulin, recombinant human transferrin, selenium, ethanolamine, and recombinant human albumin for serum-free cell culture.

Commonly replaces
Serum and undefined supplements in Treg expansion media.

Phenotype & Functional Maintenance

Hold the expanded Tregs in a stable, suppressive state, with sustained IL-2 supporting FOXP3 and function, before harvest.

Overview

Phenotype and functional maintenance preserves Treg identity through the end of culture. Tregs can lose FOXP3 expression and suppressive function, or convert toward effector phenotypes, if conditions are not maintained. The product must meet a defined phenotype, typically CD4+CD25high CD127low FOXP3+, with demonstrated suppressive function and FOXP3 locus (TSDR) stability.

Two factors are central to holding this state: sustained IL-2 signaling, which Tregs require to maintain FOXP3 and suppression, and rapamycin, which favors Tregs over conventional T cells. Rapamycin is supplied separately and is not an InVitria product.

A defined, animal-origin-free IL-2 and protein base supports phenotype stability through the rest and hold before harvest, while keeping the process free of serum- and animal-derived material.

Functions

Cytokine Signaling

Maintaining the Treg phenotype depends on continued IL-2 signaling. IL-2 sustains FOXP3 expression and the suppressive program through the late culture and the rest period before harvest; withdrawing it risks loss of identity and function. A consistent, defined IL-2 source supports phenotype and functional stability at this stage.

Recommendation
OptiLeukin™ 2

Recombinant human interleukin-2 from a non-bacterial expression system for T-cell, Treg, TIL, NK, and γδ T-cell expansion, from research to cGMP manufacturing.

Commonly replaces
Non-recombinant or undefined IL-2 preparations in Treg culture.

Carrier & Protection

Through the rest and hold before harvest, albumin continues to support Treg viability as the primary protein carrier, binding and transporting fatty acids, lipids, and metal ions, contributing antioxidant capacity, and buffering cells against handling stress while the phenotype stabilizes.

Recommendation
Optibumin® 25

Approved excipient 25% recombinant human serum albumin, supplied in bottles and closed-system friendly bags for processing, formulation, cryopreservation, and advanced biomanufacturing.

Commonly replaces
Serum, human serum albumin (HSA), or bovine serum albumin (BSA) in culture media.

Harvest & Concentration

Remove activation beads and concentrate the expanded Tregs for formulation, with defined, animal-origin-free albumin protecting cells through harvest.

Overview

Harvest and concentration collects the expanded Tregs and brings them to the density needed for formulation. Activation beads are removed magnetically, and the cells are washed to clear spent media and residual reagents, then concentrated by centrifugation or filtration with volume reduction.

Bead removal, washing, and concentration expose cells to mechanical and shear stress. Wash and concentration buffers commonly contain albumin to protect cells and limit loss during these steps.

A defined, animal-origin-free recombinant albumin protects Tregs through harvest and concentration while avoiding animal-derived residuals ahead of final formulation.

Functions

Cell Protection & Stabilization

During harvest, activation beads are removed and the cells are washed and concentrated, which exposes them to mechanical and shear stress and the risk of loss to surfaces. Albumin protects cells by transporting fatty acids and binding reactive species, buffering them against handling and shear through bead removal, washing, and concentration.

Recommendation
Optibumin® 25

Approved excipient 25% recombinant human serum albumin, supplied in bottles and closed-system friendly bags for processing, formulation, cryopreservation, and advanced biomanufacturing.

Commonly replaces
Serum or bovine serum albumin (BSA) in harvest and wash buffers.

Final Formulation & Fill Prep

Formulate the Tregs into their final matrix with defined, animal-origin-free recombinant albumin, a drug-product excipient that stabilizes the product for fill.

Overview

Final formulation and fill prep brings the Treg product to its finished form. The concentrated cells are suspended in the matrix they will be stored and administered in, then filled into the primary container, a cryobag or vial. A common formulation is an electrolyte solution with a cryoprotectant and albumin.

Albumin is a standard excipient in these matrices. It stabilizes the cells and protects them through formulation and into freezing. Because this is the drug product, excipient safety matters: plasma-derived albumin carries adventitious-agent risk that a recombinant source removes.

A defined, animal-origin-free recombinant albumin stabilizes the formulated product while keeping the final matrix free of human- and animal-derived material as it goes to fill.

Functions

Formulation Stabilization

In final formulation, the concentrated cells are suspended in the matrix they will be stored and administered in, commonly an electrolyte solution with a cryoprotectant. Albumin is a standard excipient in this matrix. It stabilizes cells, buffers them against the osmotic and handling stress of formulation and the hold before freezing, and limits adsorption to the container. As a drug-product excipient, its quality and safety profile carry into the final product.

Recommendation
Optibumin® 25

Approved excipient 25% recombinant human serum albumin, supplied in bottles and closed-system friendly bags for processing, formulation, cryopreservation, and advanced biomanufacturing.

Commonly replaces
Plasma-derived human serum albumin (HSA) used as a formulation excipient.

Cryopreservation & Storage

Freeze and store the Treg product, with defined, animal-origin-free albumin supporting cell stability and suppressive function through freeze-thaw.

Overview

Cryopreservation and storage freezes and banks the finished product. The formulated cells are cooled in a controlled-rate freezer and held in cryogenic storage, typically below -120°C in the vapor phase of liquid nitrogen, then thawed before infusion. Freezing enables banking, shipment, and dosing over a course of treatment.

Freeze-thaw exposes cells to ice formation and osmotic stress, and Tregs must retain viability and suppressive function after thaw. Cryopreservation matrices pair a penetrating cryoprotectant such as DMSO with a protein stabilizer; albumin is the standard stabilizer, buffering cells through freezing.

A defined, animal-origin-free recombinant albumin supports cryostability and recovery while keeping the frozen drug product free of human- and animal-derived material.

Functions

Freeze-Thaw Stabilization

Cryopreservation exposes cells to ice crystal formation, osmotic shifts, and membrane stress during freezing and thawing, and Tregs must retain viability and suppressive function on thaw. Cryopreservation matrices pair a penetrating cryoprotectant such as DMSO with a protein stabilizer. Albumin acts as that stabilizer, a non-penetrating component that buffers membranes against osmotic and oxidative stress and supports viability and recovery after thaw.

Recommendation
Optibumin® 25

Approved excipient 25% recombinant human serum albumin, supplied in bottles and closed-system friendly bags for processing, formulation, cryopreservation, and advanced biomanufacturing.

Commonly replaces
Plasma-derived human serum albumin (HSA) used as a cryopreservation stabilizer.